Related references
Note: Only part of the references are listed.Rationally Engineered CYP3A4 Fluorogenic Substrates for Functional Imaging Analysis and Drug-Drug Interaction Studies
Rong-Jing He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2023)
Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy
Fengling Wang et al.
DRUG METABOLISM AND DISPOSITION (2023)
Rational Design of a Two-Photon Fluorescent Probe for Human Cytochrome P450 3A and the Visualization of Mechanism-Based Inactivation
Jing Ning et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2022)
Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model
Diane Ramsden et al.
DRUG METABOLISM AND DISPOSITION (2022)
Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A
Dongzhu Tu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Optical substrates for drug-metabolizing enzymes: Recent advances and future perspectives
Qiang Jin et al.
ACTA PHARMACEUTICA SINICA B (2022)
Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond
Ruizhi Gu et al.
DRUG METABOLISM AND DISPOSITION (2022)
Endoplasmic Reticulum-Targeting Near-Infrared Fluorescent Probe for CYP2J2 Activity and Its Imaging Application in Endoplasmic Reticulum Stress and Tumor
Xiangge Tian et al.
ANALYTICAL CHEMISTRY (2022)
Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax
Ji Dong et al.
PHARMACEUTICAL RESEARCH (2022)
Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform
Md Kabir et al.
FRONTIERS IN PHARMACOLOGY (2022)
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach
Sumit Bhatnagar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1′-Hydroxylation and Testosterone 6β-Hydroxylation
Masaki Kumondai et al.
DRUG METABOLISM AND DISPOSITION (2021)
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Mingzhe Zhao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database
Lara Magro et al.
FRONTIERS IN PHARMACOLOGY (2021)
In situ target enzyme-activated near-infrared fluorescent probe: A case study of CYP2J2 using three-fragmentary molecular assembly engineering
Yanpeng Dai et al.
SENSORS AND ACTUATORS B-CHEMICAL (2021)
Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening
Hannah M. Work et al.
SCIENTIFIC REPORTS (2021)
Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018
Claire Steinbronn et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
A practical strategy to develop isoform-selective near-infrared fluorescent probes for human cytochrome P450 enzymes
Lei Feng et al.
Acta Pharmaceutica Sinica B (2021)
Primary Human Hepatocyte Spheroids as an In Vitro Tool for Investigating Drug Compounds with Low Hepatic Clearance
Julia Riede et al.
DRUG METABOLISM AND DISPOSITION (2021)
Applications of bioluminescence in biotechnology and beyond
Aisha J. Syed et al.
CHEMICAL SOCIETY REVIEWS (2021)
The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2
Xiangge Tian et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5
William C. Wright et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Sensing cytochrome P450 1A1 activity by a resorufin-based isoform-specific fluorescent probe
Qiang Jin et al.
CHINESE CHEMICAL LETTERS (2020)
Inhibition and induction of CYP enzymes in humans: an update
Jukka Hakkola et al.
ARCHIVES OF TOXICOLOGY (2020)
Target Enzyme-Activated Two-Photon Fluorescent Probes: A Case Study of CYP3A4 Using a Two-Dimensional Design Strategy
Jing Ning et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Ultrasensitive near-infrared fluorescent probe with large stokes shift for real-time tracing of CYP1A1 in living cells and zebrafish model
Tianzi Xue et al.
SENSORS AND ACTUATORS B-CHEMICAL (2019)
Target Enzyme-Activated Two-Photon Fluorescent Probes: A Case Study of CYP3A4 Using a Two-Dimensional Design Strategy (vol 58, pg 9959, 2019)
J. Ning et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Cytochrome P450-The Wonderful Nanomachine Revealed through Dynamic Simulations of the Catalytic Cycle
Kshatresh Dutta Dubey et al.
ACCOUNTS OF CHEMICAL RESEARCH (2019)
Molecular Design Strategy to Construct the Near-Infrared Fluorescent Probe for Selectively Sensing Human Cytochrome P450 2J2
Jing Ning et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
A highly selective ratiometric fluorescent probe based on naphthalimide for detection and imaging of CYP1A1 in living cells and zebrafish
Hefang Ji et al.
ANALYST (2019)
Cytochrome P450 Structure, Function and Clinical Significance: A Review
Palrasu Manikandan et al.
CURRENT DRUG TARGETS (2018)
Synthesis of a selective ratiometric fluorescent probe based on Naphthalimide and its application in human cytochrome P450 1A
Xiuxuan Zhang et al.
TALANTA (2018)
A highly sensitive and selective two-photon fluorescent probe for real-time sensing of cytochrome P450 1A1 in living systems
Jing Ning et al.
MATERIALS CHEMISTRY FRONTIERS (2018)
A practical strategy to design and develop an isoform-specific fluorescent probe for a target enzyme: CYP1A1 as a case study
Zi-Ru Dai et al.
CHEMICAL SCIENCE (2017)
Inhibiting Firefly Bioluminescence by Chalcones
Huateng Zhang et al.
ANALYTICAL CHEMISTRY (2017)
Determination of 7α-OH cholesterol by LC-MS/MS: Application in assessing the activity of CYP7A1 in cholestatic minipigs
Changhong Yun et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2016)
Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Xin He et al.
CURRENT DRUG METABOLISM (2015)
A Highly Selective Ratiometric Two-Photon Fluorescent Probe for Human Cytochrome P450 1A
Zi-Ru Dai et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications
Arthur I. Cederbaum
REDOX BIOLOGY (2015)
Cancer, Inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents
R. Donald Harvey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients
Andrew K. L. Goey et al.
CANCER TREATMENT REVIEWS (2013)
Discovery of 5-Benzyl-3-phenyl-4,5-dihydroisoxazoles and 5-Benzyl-3-phenyl-1,4,2-dioxazoles as Potent Firefly Luciferase Inhibitors
Pekka K. Poutiainen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Human cytochromes P450 in health and disease
Daniel W. Nebert et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2013)
Modulation of Cytochrome-P450 Inhibition (CYP) in Drug Discovery: A Medicinal Chemistry Perspective
Sanjay Kumar et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates
James J. Cali et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Transcriptional Profiling of Human Liver Identifies Sex-Biased Genes Associated with Polygenic Dyslipidemia and Coronary Artery Disease
Yijing Zhang et al.
PLOS ONE (2011)
Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction
Zhong-Ze Fang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Application of Cytochrome P450 Drug Interaction Screening in Drug Discovery
Robert S. Foti et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2010)
Firefly luciferase inhibition
Joao M. M. Leitao et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY (2010)
Prediction of Drug-Drug Interactions based on Time-Dependent Inhibition from High Throughput Screening of Cytochrome P450 3A4 Inhibition
Nobuo Sekiguchi et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease
Mario Congiu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries
Henrike Veith et al.
NATURE BIOTECHNOLOGY (2009)
Mechanism-based inactivation of human cytochromes P450s: Experimental characterization, reactive intermediates, and clinical implications
Paul F. Hollenberg et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Simultaneous quantitation of 17 alpha-hydroxyprogesterone caproate, 17 alpha-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS)
Shimin Zhang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Exposure of the elderly to potential nephrotoxic drug combinations in Belgium
Hilde L. E. Smets et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
Evaluation of fluorescence- and mass spectrometry - Based CYP inhibition assays for use in drug discovery
Leslie Bell et al.
JOURNAL OF BIOMOLECULAR SCREENING (2008)
Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes
Sirimas Sudsakorn et al.
DRUG METABOLISM AND DISPOSITION (2007)
Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions
R. Scott Obach et al.
DRUG METABOLISM AND DISPOSITION (2007)
Luminogenic cytochrome P450 assays
James J. Cali et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions
RS Obach et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
High throughput P450 inhibition screens in early drug discovery
G Zlokarnik et al.
DRUG DISCOVERY TODAY (2005)
Highly miniaturized formats for in vitro drug metabolism assays using Vivid® fluorescent substrates and recombinant human cytochrome P450 enzymes
OV Trubetskoy et al.
JOURNAL OF BIOMOLECULAR SCREENING (2005)
Database analyses for the prediction of in vivo drug-drug interactions from in vitro data
K Ito et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes
MT Donato et al.
DRUG METABOLISM AND DISPOSITION (2004)
Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes
A Ghosal et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2003)
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities
J Venhorst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling
M Spatzenegger et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic Vivid® P450 substrate
BD Marks et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2002)
Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department
CM Hohl et al.
ANNALS OF EMERGENCY MEDICINE (2001)
Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4
AB Renwick et al.
XENOBIOTICA (2001)
Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms
AB Renwick et al.
XENOBIOTICA (2000)